Key result
Active methamphetamine use in methamphetamine-associated cardiomyopathy links to biventricular thrombus and PE.
Why the study?
Limited evidence exists regarding the increased risk of thrombogenicity and intracardiac thrombi in patients with methamphetamine-associated cardiomyopathy (MACM).
Design
Case report
Follow-up
2.5 months
Authors
Loading...
MACM may increase intracardiac thrombus risk; this Level 5 case leaves open the need for prospective confirmation before changing practice.
Case Report (n=1)
Methamphetamine-associated cardiomyopathy may be associated with increased thrombogenicity and intracardiac thrombi, warranting a low threshold for surveillance echocardiography.
Zaidi et al. (2022) conducted a case report in Methamphetamine-associated cardiomyopathy (n=1). Methamphetamine use was evaluated. Active methamphetamine use in patients with methamphetamine-associated cardiomyopathy can lead to increased thrombus burden with biventricular involvement and pulmonary embolism.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: